Brecanavir

DB04887InvestigationalSmall molecule

Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. In July 2006, Vertex indicated that it expected GSK to... In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV.

Mechanism: Brecanavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Curator reviewed
Primary indication: For the treatment of HIV-1 infection in combination with other antiretroviral agents.Curator reviewed
Formula / weight: C₃₃H₄₁N₃O₁₀S₂ · 703.823 g/mol (avg)
Code names: GSK 640385 · GW 0385 · GW-640385 · GW-640385X · GW-64085X · VX-385

Resolves to

Compound

UNIIE367I8C7FICAS313682-08-5ChEMBLCHEMBL206031ChEBI748738PubChem5743186KEGGD03253

Structure

InChIKeyJORVRJNILJXMMG-OLNQLETPSA-NSMILES

[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=C(OCC2=CSC(C)=N2)C=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC2=C(OCO2)C=C1

Targets

Q72874polP03366gag-pol

What you can answer from here — as of October 01, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brecanavir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account